FDA Panel: Heart Closure Device Safety Data Demands Further Study
This article was originally published in The Gray Sheet
More study is required to make sense of the adverse event rates associated with two marketed atrial septal defect occluders, a May 24 FDA panel concluded. St. Jude Medical, in particular, should start a new prospective study for its Amplatzer device, the panel recommends.
You may also be interested in...
Future prospects for devices that close patent foramen ovale heart defects to prevent recurrent strokes remain in some doubt as researchers continue to mull recent data.
St. Jude Medical will become the market leader in structural heart defect closure devices with its planned $1.3 billion purchase of AGA Medical.
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?